Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.
2.

Signaling inhibitors in metastatic renal cell carcinoma.

Escudier B.

Cancer J. 2008 Sep-Oct;14(5):325-9. doi: 10.1097/PPO.0b013e3181867605.

PMID:
18836338
3.

[Novelties in the treatment for advanced renal-cell cancer].

Maráz A.

Orv Hetil. 2011 Apr 24;152(17):655-62. doi: 10.1556/OH.2011.29100. Review. Hungarian.

PMID:
21464023
4.

[Medical treatment of renal cell carcinoma].

Guy L, Bay JO, Bastide C, Mahammedi H, Bruyere F, Karsenty G.

Prog Urol. 2013 Nov;23(15):1225-37. doi: 10.1016/j.purol.2013.09.011. Review. French.

PMID:
24183081
5.

Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.

Iacovelli R, Palazzo A, Trenta P, Mezi S, Pellegrino D, Naso G, Cortesi E.

Am J Clin Oncol. 2014 Dec;37(6):611-5. doi: 10.1097/COC.0b013e31827de888. Review.

PMID:
23388560
6.

Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.

Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK.

Clin Genitourin Cancer. 2014 Aug;12(4):262-9. doi: 10.1016/j.clgc.2014.03.002.

PMID:
24795159
7.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ.

J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961.

PMID:
24297950
8.

Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.

Beuselinck B, Lerut E, Wolter P, Dumez H, Berkers J, Van Poppel H, Joniau S, Oyen R, De Wever L, Strijbos M, Paridaens R, Schöffski P.

Clin Genitourin Cancer. 2014 Oct;12(5):e205-14. doi: 10.1016/j.clgc.2014.04.004.

PMID:
24861951
9.

Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.

Pouessel D, Culine S.

Expert Rev Anticancer Ther. 2006 Dec;6(12):1761-7. Review.

PMID:
17181490
10.

Sunitinib, sorafenib and mTOR inhibitors in renal cancer.

Radulovic S, Bjelogrlic SK.

J BUON. 2007 Sep;12 Suppl 1:S151-62. Review.

PMID:
17935273
11.

Maturing of renal cancer therapeutics.

Stadler WM.

J Clin Oncol. 2014 Mar 10;32(8):722-4. doi: 10.1200/JCO.2013.54.1748. No abstract available.

PMID:
24516015
12.

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V.

Eur Urol. 2010 Dec;58(6):906-11. doi: 10.1016/j.eururo.2010.09.008.

PMID:
20884115
13.

Targeted therapies in metastatic renal cancer in 2009.

Bastien L, Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A.

BJU Int. 2009 May;103(10):1334-42. doi: 10.1111/j.1464-410X.2009.08454.x. Review.

14.

Major treatment improvements encourage kidney cancer researchers to seek further gains.

Tuma RS.

J Natl Cancer Inst. 2008 Sep 3;100(17):1202-3. doi: 10.1093/jnci/djn316. No abstract available.

15.

Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.

Blesius A, Beuselinck B, Chevreau C, Ravaud A, Rolland F, Oudard S, Escudier B.

Clin Genitourin Cancer. 2013 Jun;11(2):128-33. doi: 10.1016/j.clgc.2012.12.001.

PMID:
23332872
16.

[Advanced renal carcinomas with special situations. How to treat them?].

Pouessel D, Patard JJ, Culine S.

Bull Cancer. 2010;97:83-90. doi: 10.1684/bdc.2010.1073. French.

PMID:
20418207
17.

[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

Miller K, Bergmann L, Gschwend J, Keilholz U.

Aktuelle Urol. 2011 Jul;42(4):242-6. doi: 10.1055/s-0031-1271548. German.

PMID:
21720974
18.

Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.

Weikert S, Kempkensteffen C, Busch J, Johannsen M, Grünwald V, Zimmermann K, Flörcken A, Westermann J, Weinkauf L, Miller K, Keilholz U.

World J Urol. 2013 Aug;31(4):805-9. doi: 10.1007/s00345-011-0676-1.

PMID:
21512806
19.

Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.

Hainsworth JD, Rubin MS, Arrowsmith ER, Khatcheressian J, Crane EJ, Franco LA.

Clin Genitourin Cancer. 2013 Sep;11(3):270-5. doi: 10.1016/j.clgc.2013.04.006.

PMID:
23665131
20.

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.

Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S.

J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011.

PMID:
25046616
Items per page

Supplemental Content

Support Center